Skip to content

Study · Non-randomized trial · n = 14 · 1983

7 results

In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin alpha 1.

Dillman RO, Beauregard JC, Zavanelli MI, Halliburton BL, Wormsley S, Royston I

Journal of biological response modifiers1 Jan 1983Cited by 2 (Europe PMC)

PMID6315897 (opens in a new tab)PepBankPUB-06315897
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with advanced cancer, 28.4% of abnormal in vitro immune tests improved after thymosin alpha‑1.

    In plain wordsIn patients with advanced cancer, thymosin alpha‑1 improved 28.4% of immune tests that were abnormal before treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseAbnormal in vitro immune tests improved after TA1
    Study

    n = 14

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.6-9.6 mg/m2 · intramuscular · single injectionAs given in this study (human).

    Measurements

    abnormal tests improved
    28.4%
    TA1

    Source sentences

    Summary
    Overall, 28.4 and 18.3% of abnormal tests were improved following TA1 and TF5, respectively.
    1 context sentence
    Summary · context
    We treated 14 patients with thymosin fraction 5 (TF5), and 14 patients with thymosin alpha 1 (TA1) over the dose ranges of 60-960 mg/m2 and 0.6-9.6 mg/m2, respectively.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with advanced cancer, 13 of 14 who received thymosin alpha‑1 showed significant improvement in at least one in vitro test.

    In plain wordsIn patients with advanced cancer, 13 of 14 given thymosin alpha‑1 had a clear improvement in at least one immune test.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePatients with improvement in at least one in vitro test
    Study

    n = 14

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.6-9.6 mg/m2 · intramuscular · single injectionAs given in this study (human).

    Measurements

    patients with improvement
    13 of 14
    TA1

    Source sentences

    Summary
    13 of 14 who received TA1 showed significant improvement in at least one in vitro test.
    1 context sentence
    Summary · context
    We treated 14 patients with thymosin fraction 5 (TF5), and 14 patients with thymosin alpha 1 (TA1) over the dose ranges of 60-960 mg/m2 and 0.6-9.6 mg/m2, respectively.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with advanced cancer, thymosin alpha‑1 at 1.2 mg/m2 was associated with substantial improvement in 46% of abnormal tests.

    In plain wordsIn patients with advanced cancer, a thymosin alpha‑1 dose of 1.2 mg/m2 was linked to improvement in 46% of abnormal immune tests.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseImprovement in abnormal tests at 1.2 mg/m2
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.2 mg/m2 · intramuscular · single injectionAs given in this study (human).

    Measurements

    abnormal tests substantially improved
    46%
    TA1 1.2 mg/m2

    Source sentences

    Summary
    1.2 mg/m2 of TA1 was associated with substantial improvement in 46% of abnormal tests.
    1 context sentence
    Summary · context
    We treated 14 patients with thymosin fraction 5 (TF5), and 14 patients with thymosin alpha 1 (TA1) over the dose ranges of 60-960 mg/m2 and 0.6-9.6 mg/m2, respectively.

Studies that did not test the peptide alone4

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with advanced cancer, no tumor responses were seen after thymosin fraction 5 or thymosin alpha‑1 (pooled).

    In plain wordsIn patients with advanced cancer, no tumors shrank after either thymosin product.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTumor response
    Study

    n = 28

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Tumor responses were not seen
    1 context sentence
    Summary · context
    We treated 14 patients with thymosin fraction 5 (TF5), and 14 patients with thymosin alpha 1 (TA1) over the dose ranges of 60-960 mg/m2 and 0.6-9.6 mg/m2, respectively.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    In patients with advanced cancer, thymosin fraction 5 and thymosin alpha‑1 were well tolerated as single intramuscular injections (pooled).

    In plain wordsIn patients with advanced cancer, single injections of either thymosin product were well tolerated.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTolerability of single injections
    Study

    n = 28

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    TF5 and TA1 are well tolerated as single i.m. injections, and have immunorestorative potential in cancer patients.
    1 context sentence
    Summary · context
    We treated 14 patients with thymosin fraction 5 (TF5), and 14 patients with thymosin alpha 1 (TA1) over the dose ranges of 60-960 mg/m2 and 0.6-9.6 mg/m2, respectively.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 06HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialOther

    In patients with advanced cancer, 16% of normal in vitro tests became abnormal after therapy with thymosin fraction 5 or thymosin alpha‑1 (pooled).

    In plain wordsIn patients with advanced cancer, 16% of normal immune tests became abnormal after treatment with either thymosin product.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableNormal in vitro tests that became abnormal after therapy
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Measurements

    normal tests became abnormal
    16%
    TF5 and TA1 pooled

    Source sentences

    Summary
    On the other hand, 16% of normal tests became abnormal after therapy.
    1 context sentence
    Summary · context
    We treated 14 patients with thymosin fraction 5 (TF5), and 14 patients with thymosin alpha 1 (TA1) over the dose ranges of 60-960 mg/m2 and 0.6-9.6 mg/m2, respectively.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 07HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialOther

    In patients with advanced cancer, most in vitro immune test responses after thymosin fraction 5 or thymosin alpha‑1 (pooled) occurred within 24-48 h and seldom persisted beyond 72 h.

    In plain wordsIn patients with advanced cancer, most immune test changes after either thymosin product came within 24-48 hours and seldom lasted beyond 72 hours.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableTiming and duration of in vitro immune test responses
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Most of these responses occurred within 24-48 h and seldom persisted beyond 72 h.
    1 context sentence
    Summary · context
    We treated 14 patients with thymosin fraction 5 (TF5), and 14 patients with thymosin alpha 1 (TA1) over the dose ranges of 60-960 mg/m2 and 0.6-9.6 mg/m2, respectively.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.